$ROIV

MANCHESTER KEITH S sold $49.4M of ROIV (indirect holdings)

MANCHESTER KEITH S sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.

Original reporting
SEC EDGAR · MANCHESTER KEITH S
Published Jul 1, 2026, 12:38 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 1, 2026, 1:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ROIV
Neutral
medium confidence
Mentioned
$ROIV
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVNeutralMed
01

Why it matters

A director’s ~$49.35M open-market sale can influence short-term sentiment, but it does not by itself change company fundamentals or guidance.

02

Market read

Traders may reassess ROIV positioning around insider-selling sentiment, while waiting for additional catalysts (earnings, trial updates, financing, or regulatory news).

03

What to watch

The transactions are spread across multiple days and are indirect holdings; traders should check for any concurrent option exercises/other insider buys in nearby filings before over-weighting the sale.

Relevance 7/10Novelty 6/10Timing: Filed 2026-06-30 after sales dated 2026-06-26 to 2026-06-30

Background

The article is an SEC Form 4 insider transaction disclosure for Roivant Sciences Ltd.

Company-level read

Ticker impact

$ROIVNeutralMedium confidence
Context

Roivant Sciences director Manchester Keith S sold 1,438,163 ROIV shares in open-market transactions for ~$49.35M, per Form 4.

Expected impact

Short-term: slight negative/neutral drift possible; medium-term: limited signal value unless follow-on filings show continued selling or a new catalyst emerges.

Evidence & confidence

The filing is primary-source and sizable, but the article notes no pre-arranged 10b5-1 plan, which increases interpretive uncertainty rather than providing a clear directional fundamental change.

Market effects

Limited sector read-through; this is company-specific insider activity rather than a biotech/sector-wide catalyst.

Minimal; US-listed issuer Form 4 typically affects single-name sentiment more than broader indices.

Low; no cross-border deal/regulatory action described.

Counterpoint

Without a 10b5-1 plan, the sale could reflect diversification/tax planning rather than a negative view on fundamentals.

Key entities

  • Roivant Sciences Ltd.

    Subject of the Form 4 insider sale; ticker ROIV.

  • Manchester Keith S

    Director who sold 1,438,163 shares in open-market transactions; indirect holdings.

Related articles

$ROIVMed

Roivant Sciences Ltd. (ROIV): Results of Operations and Financial Condition

Roivant Sciences Ltd. (ROIV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q1fy2026roivantearningsrel.htm EX-99.1 Document Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update • Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track fo

$ABUSMedAI 8/10

Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech

Arbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.

$ROIVHighAI 9/10

TD Cowen Raises its Price Target on Roivant Sciences (ROIV)

TD Cowen raised its price target on Roivant Sciences (ROIV) to $41 from $38 and kept a Buy rating, citing “impressive” Phase 2b D2T RA topline data for IMVT-1402 (ACR20 73%, ACR50 55%, ACR70 36%) and additional 2026 catalysts. Citi raised its target to $42 from $35, also Buy. Roivant reported Q4 EPS 28c vs -35c consensus and revenue $2.52M vs $3.91M.